Comparing Two Brain Stimulation Treatments for Major Depression
Compares magnetic seizure therapy with electroconvulsive therapy in adults with major depression.
Plain-language title generated from the registry record
Registry title: Effectiveness of MST Versus ECT for Major Depressive Episode
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06409325, who can take part
Where in China
- Shanghai Mental Health CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Mental Health Center
- Trial code
- NCT06409325
- Record updated
- 22 August 2024
- Original description
Despite advancements in Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), there remains a need for further research to replicate clinical outcomes and understand the therapeutic targets of these treatments. This study aims to address these gaps through a double-blinded, randomized, non-inferiority investigation comparing the efficacy, tolerability, cognitive adverse effects, and neurophysiological biomarkers of MST and bilateral ECT in patients with MDD.Read full original descriptionShow less
Effectiveness of Magnetic Seizure Therapy Versus Electroconvulsive Therapy for Major Depressive Episode
Despite advancements in Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), there remains a need for further research to replicate clinical outcomes and understand the therapeutic targets of these treatments. This study aims to address these gaps through a double-blinded, randomized, non-inferiority investigation comparing the efficacy, tolerability, cognitive adverse effects, and neurophysiological biomarkers of MST and bilateral ECT in patients with MDD.
Inclusion: Participants must meet the diagnostic criteria for MDD as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); Participants must have a baseline score of 18 or higher on the 24-item Hamilton Depression Rating Scale (HDRS-24); During the trial's treatment period, participants must be using a single antidepressant medication at a stable dose; Participants must be between the ages of 18 and 65 years; Informed consent from both parents and legal guardians is required.
Exclusion: Individuals currently taking antiepileptic drugs, benzodiazepines, or other medications that may affect seizure activity will be excluded from the study; Individuals currently participating in another concurrent clinical trial will not be eligible for inclusion; Individuals with current or history of organic brain disorders or neurological disorders will be excluded from the study; Individuals with cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain will be excluded from participation; Participants with a Wechsler Abbreviated Scale of Intelligence (WASI) score of less than 70 will be excluded; Those with exposure to ECT, modified ECT, MST, transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neurostimulation treatments in last 6 months will be excluded; Pregnant or lactating individuals will be excluded from the study; Participants who refuse to provide informed consent to participate in the trial will be excluded; Other circumstances deemed unsuitable for participation by researchers will result in exclusion.